Superluminal’s $60M series B to drive first clinical study: Finance Report

During a quiet week ahead of the U.S. holiday, Superluminal announced a $60 million series B round intended to support its first candidate’s entry into the clinic.

A crossover syndicate led by BVF Partners backed Superluminal Medicines Inc. in the round, with Deep Track Capital and Perceptive Advisors joining as new investors. Series A and seed round leader RA Capital Management also participated, among other previous investors...